Drug maker Novartis loses India patent battle
India’s Supreme Court on Monday rejected drug maker Novartis AG’s attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the …
Categories: Uncategorized Tags: a-landmark-decision, activists-say, ensures-poor, landmark-decision, monday, novartis, patients-around, rejected-drug, supreme, supreme-court, the, updated-version
UK health cost body backs Novartis asthma drug in fresh U-turn
Britain’s healthcost-effectivness watchdog NICE said it planned to recommend theuse of Novartis’s severe asthma drug Xolair afterprevaricating for months over whether it should be paid for onthe taxpayer-funded …
Categories: Uncategorized Tags: for-months, nice, novartis, onthe-taxpayer-funded, over-whether, paid-for, recommend-theuse, said-it-planned, severe-asthma, taxpayer, whether-it-should, xolair
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine …
EAST HANOVER, N.J., Dec. 14, 2012 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor ® (pasireotide) injection for the treatment of adult patients …
Categories: Uncategorized Tags: adult-patients, announced-today, east, fda, has-approved, injection-for, novartis, signifor, the-treatment
Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at …
EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ — Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted …
Categories: Uncategorized Tags: 140-presentations, a-from-its, east, from-its, key-data, meetings-devoted, novartis, sentations-on-key, the-leading, will-highlight, year-end-scientific
Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at …
EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ — Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted …
Categories: Uncategorized Tags: 140-presentations, a-from-its, east, from-its, key-data, meetings-devoted, novartis, sentations-on-key, the-leading, will-highlight, year-end-scientific
Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at …
EAST HANOVER, N.J., Nov. 28, 2012 /PRNewswire/ — Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted …
Categories: Uncategorized Tags: 140-presentations, a-from-its, east, from-its, key-data, meetings-devoted, novartis, sentations-on-key, the-leading, will-highlight, year-end-scientific
Penn's Long Term Relationship with the Leukemia & Lymphoma Society Laid Groundwork for Transformative Therapies for …
PHILADELPHIA — In August, The University of Pennsylvania announced a major new strategic partnership with Novartis to further develop novel immunotherapies using chimeric antigen receptor (CAR) technology developed in the laboratories of Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Perelman School of Medicine and …
Categories: Uncategorized Tags: develop, laboratories, laboratory, major-new, novartis, perelman-school, professor, richard, using-chimeric
Novartis Canada Resumes Seasonal Influenza Vaccine Distribution as Health Canada Lifts Suspension
Canadians urged to protect themselves for the coming flu season.Video: B-Roll – October 31, 2012: John Dorsey Head, Vaccines and Diagnostics at Novartis Pharmaceuticals Canada Inc. receiving Agriflu ® …
Categories: Uncategorized Tags: agriflu, coming, coming-flu, diagnostics, dorsey, dorsey-head, for-the, iagnostics-at-novartis, novartis, novartis-pharmaceuticals, october, vaccines